Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 12/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423893 | 1.00 | PIM1 (0.70) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1424084 | 0.90 | PIK3CG (0.71) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1424085 | 0.90 | PIK3CG (0.71) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1423993 | 0.87 | PIM1 (0.68) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1423991 | 0.87 | PIM1 (0.68) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1424538 | 0.87 | PIK3CG (0.57) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1424537 | 0.87 | PIK3CG (0.57) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1424076 | 0.84 | PIM1 (0.71) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL1423761 | 0.84 | PIM1 (0.71) | PIM1PIM2PIK3CGFYNMAPT | |
| SCHEMBL4328408 | 0.82 | PIK3CG (0.72) | PIM1PIM2PIK3CGMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081933-B1 | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | claimed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | claimed |
| EP-2081933-B1 | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | ATR, ATM, CHEK1 | PIM1 452/4885PIM2 846/4885PIK3CG 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.